Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Cyclophosphamide Drug Market Share, Size, Growth, Analysis, Forecast: By Route of Administration: Oral, Parenteral; By Dose: High Dose, Low Dose; By Disease: Cancer Disease, Autoimmune Disease, AL Amyloidosis, Others; By Distribution Channel: Hospital Based Pharmacies, Others; Regional Analysis; Supplier Landscape; 2023-2031

Global Cyclophosphamide Drug Market Outlook

The growth of the global Cyclophosphamide drug market is expected to grow with a CAGR of 2.2% during the forecast period of 2023-2031, driven by the growing incidences of cancer. The market is expected to reach a value of USD 806 million by 2031.

 

Cyclophosphamide Drug Market: Insights

These drugs are classified as alkylating agents. It slows or stops the growth of cancer cells in the body when used in the treatment of cancer. It suppresses the body's immune system when used to treat nephrotic syndrome.  A kidney condition, known as nephrotic syndrome, makes the body excrete excessive amounts of protein in urine. The clusters of tiny blood capillaries in the kidneys that filter waste and extra water from the blood are typically damaged by nephrotic syndrome.

 

Cyclophosphamide, solely or in combination with other drugs, is used for the treatment of various cancers, like lymphoma, myeloma, and leukaemia. It is also used in the therapy of retinoblastoma, neuroblastoma, ovarian cancer, and breast cancer.  Metabolites is the main way through which the drug is excreted from the body.   

 

Neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhoea are the adverse effects that are most frequently reported.  

 

According to the Cyclophosphamide drug market research report, the market can be categorised into the following segments: 

Market Breakup by Route of Administration 

  • Oral
  • Parenteral

 

Market by Dose

  • High Dose
  • Low Dose

 

Market by Disease

  • Oncology
  • Autoimmune Diseases
  • AL Amyloidosis
  • Others

 

Market by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Market Scenario

The Cyclophosphamide drug is on the list of essential medicines by WHO. The demand for the drug is increasing with increased cases of cancer among the population in the future. More combinations are under development and trial for the treatment of wide spectrum of diseases.

 

It is used as an alkylating drug to stop and slow the growth of tumours by directly damaging DNA and cross-linking guanine bases in DNA double-helix strands. It is used to treat several cancers, including lung cancer, breast cancer, eye cancer, blood cell cancer, white bone, and bone marrow cancer. This drug is used to treat a particular form of kidney illness in children with nephrotic syndrome. Product consumption will increase as healthcare industry grows. Therefore, throughout the anticipated period, the growth of the market would be driven by the rising demand.

 

The Cyclophosphamide drug market in Asia Pacific is expected to increase gradually. The rapid rise in the healthcare industry can be attributed to the increase. Furthermore, an increasing number of disorders, such as blood cell cancer and lung cancer, have increased the product in the nephrotic syndrome and AL amyloidosis, which will drive market expansion in North America. Increased use of Cyclophosphamide drugs in hospitals and clinics is driving the growth in Europe. 

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global Cyclophosphamide drug market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

 

  • Baxter Laboratories Ltd.
  • Novartis AG
  • Himka Pharmaceuticals Plc.
  • Amneal Pharmaceuticals LLC
  • NorthStar Rx LLC
  • Aurobindo Pharma Ltd.
  • CSC Pharmaceutical International
  • Jiangsu Hengrui Medicine Co Ltd
  • Nodus Oncology
  • Abbive, Inc.
  • Theravance Biopharm, Inc. 
  • Sanofi S.A.
  • Roxane Laboratories Pvt Ltd
  • LGM Pharma Llc

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Route of Administration
  • Dose
  • Disease
  • Distribution Channel
  • Region
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Dose
  • High Dose
  • Low Dose
Breakup by Disease
  • Cancer Disease
  • Autoimmune Disease
  • AL Amyloidosis
  • Others
Breakup by Distribution Channel
  • Hospital Based Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Merger and Acquisitions
    • Certifications
Companies Covered
  • Baxter Laboratories Inc.
  • Novartis AG
  • Hikma Pharmaceuticals Plc.
  • Amneal Pharmaceuticals Llc
  • NorthStar Rx Llc
  • Aurobindo Pharma Ltd.
  • CSC Pharmaceuticals International
  • Jiangsu Hengrui Medicine Co Ltd
  • Nodus Oncology
  • Abbive, Inc.
  • Theravance Biopharma, Inc.
  • Sanofi S.A.
  • Roxane Laboratories Pvt Ltd
  • LGM Pharma Llc

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Cyclophosphamide Drug Overview

    4.1    Drug Overview
        4.1.1    Pharmacodynamics 
        4.1.2    Pharmacokinetics
        4.1.3    Adverse Events
5    Patient Profile
    5.1    Patient Profile Overview 
    5.2    Patient Psychology and Emotional Impact Factors 
    5.3    Risk Assessment and Treatment Success Rate 
6    Global Cyclophosphamide Drug Market
    6.1    Global Cyclophosphamide Drug Market Overview
    6.2    Global Cyclophosphamide Drug Market Analysis 
        6.2.1    Market Overview
            6.2.1.1    Global Cyclophosphamide Drug Market Historical Value (2016-2022) 
            6.2.1.2    Global Cyclophosphamide Drug Market Forecast Value (2023-2031)
    6.3    Global Cyclophosphamide Drug Market by Route of Administration
        6.3.1    Market Overview
            6.3.1.1    Oral
            6.3.1.2    Parenteral
    6.4    Global Cyclophosphamide Drug Market by Dose
        6.4.1    Market Overview
            6.4.1.1    High Dose
            6.4.1.2    Low Dose
    6.5    Global Cyclophosphamide Drug Market by Disease
        6.5.1     Market Overview
            6.5.1.1    Cancer Disease
            6.5.1.2    Autoimmune Disease
            6.5.1.3    AL Amyloidosis
            6.5.1.4    Others
    6.6    Global Cyclophosphamide Drug Market by Distribution Channel
        6.6.1    Market Overview
            6.6.1.1    Hospital Based Pharmacies
            6.6.1.2    Online Pharmacies
            6.6.1.3    Retail Pharmacies
    6.7    Global Cyclophosphamide Drug Market by Region
        6.7.1    Market Overview
            6.7.1.1    North America 
                6.7.1.1.1    Historical Trend (2016-2022)
                6.7.1.1.2    Forecast Trend (2023-2031)
            6.7.1.2    Europe
                6.7.1.2.1    Historical Trend (2016-2022)
                6.7.1.2.2    Forecast Trend (2023-2031)
            6.7.1.3    Asia Pacific
                6.7.1.3.1    Historical Trend (2016-2022)
                6.7.1.3.2    Forecast Trend (2023-2031)
            6.7.1.4    Latin America
                6.7.1.4.1    Historical Trend (2016-2022)
                6.7.1.4.2    Forecast Trend (2023-2031)
            6.7.1.5    Middle East and Africa
                6.7.1.5.1    Historical Trend (2016-2022)
                6.7.1.5.2    Forecast Trend (2023-2031)
7    North America Cyclophosphamide Drug Market
    7.1    United States of America
        7.1.1    Historical Trend (2016-2022)
        7.1.2    Forecast Trend (2023-2031)
    7.2    Canada 
        7.2.1    Historical Trend (2016-2022)
        7.2.2    Forecast Trend (2023-2031)
8    Europe Cyclophosphamide Drug Market
    8.1    United Kingdom
        8.1.1    Historical Trend (2016-2022)
        8.1.2    Forecast Trend (2023-2031)
    8.2    Germany
        8.2.1    Historical Trend (2016-2022)
        8.2.2    Forecast Trend (2023-2031)
    8.3    France
        8.3.1    Historical Trend (2016-2022)
        8.3.2    Forecast Trend (2023-2031)
    8.4    Italy
        8.4.1    Historical Trend (2016-2022)
        8.4.2    Forecast Trend (2023-2031)
9    Asia Pacific Cyclophosphamide Drug Market
    9.1    China
        9.1.1    Historical Trend (2016-2022)
        9.1.2    Forecast Trend (2023-2031)
    9.2    Japan
        9.2.1    Historical Trend (2016-2022)
        9.2.2    Forecast Trend (2023-2031)
    9.3    India
        9.3.1    Historical Trend (2016-2022)
        9.3.2    Forecast Trend (2023-2031)
    9.4    ASEAN
        9.4.1    Historical Trend (2016-2022)
        9.4.2    Forecast Trend (2023-2031)
    9.5    Australia
        9.5.1    Historical Trend (2016-2022)
        9.5.2    Forecast Trend (2023-2031)
10    Latin America Cyclophosphamide Drug Market
    10.1    Brazil
        10.1.1    Historical Trend (2016-2022)
        10.1.2    Forecast Trend (2023-2031)
    10.2    Argentina
        10.2.1    Historical Trend (2016-2022)
        10.2.2    Forecast Trend (2023-2031)
    10.3    Mexico
        10.3.1    Historical Trend (2016-2022)
        10.3.2    Forecast Trend (2023-2031)
11    Middle East and Africa Cyclophosphamide Drug Market
    11.1    Saudi Arabia
        11.1.1    Historical Trend (2016-2022)
        11.1.2    Forecast Trend (2023-2031)
    11.2    United Arab Emirates
        11.2.1    Historical Trend (2016-2022)
        11.2.2    Forecast Trend (2023-2031)
    11.3    Nigeria
        11.3.1    Historical Trend (2016-2022)
        11.3.2    Forecast Trend (2023-2031)
    11.4    South Africa
        11.4.1    Historical Trend (2016-2022)
        11.4.2    Forecast Trend (2023-2031)
12    Current Scenario Evaluation and Regulatory Framework
    12.1    Emerging Therapies and Clinical Trials Synopsis
    12.2    Patent Landscape
        12.2.1    Patent Overview
            12.2.1.1    Patent Status and Expiry
            12.2.1.2    Timelines from Drug Development to Commercial Launch
            12.2.1.3    New Drug Application
            12.2.1.3    Documentation and Approval Process
    12.3    Cost of Treatment
    12.4    Investment Scenarios
    12.5    Regulatory Framework
        12.5.1    Regulatory Overview
            12.5.1.1    US FDA
            12.5.1.2    EU EMA
            12.5.1.3    INDIA CDSCO
            12.5.1.4    JAPAN PMDA
            12.5.1.5    Others
13    Challenges and Unmet Need
    13.1    Treatment Pathway Challenges
    13.2    Compliance and Drop-Out Rate
    13.3    Awareness and Prevention Gaps
14    Global Cyclophosphamide Drug Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Drug Adoption Parameters
    14.4    Porter’s Five Forces Model
    14.5    Key Demand Indicators
    14.6    Key Price Indicators 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Baxter Laboratories Inc.
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievement
        15.1.4    Merger and Acquisitions
        15.1.5    Certifications
    15.2     Novartis AG
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievement
        15.2.4    Merger and Acquisitions
        15.2.5    Certifications
    15.3     Hikma Pharmaceuticals Plc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievement
        15.3.4    Merger and Acquisitions
        15.3.5    Certifications
    15.4     Amneal Pharmaceuticals Llc
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievement
        15.4.4    Merger and Acquisitions
        15.4.5    Certifications
    15.5     NorthStar Rx Llc
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievement
        15.5.4    Merger and Acquisitions
        15.5.5    Certifications
    15.6     Aurobindo Pharma Ltd.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievement
        15.6.4    Merger and Acquisitions
        15.6.5    Certifications
    15.7    CSC Pharmaceuticals International
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievement
        15.7.4    Merger and Acquisitions
        15.7.5    Certifications
    15.8    Jiangsu Hengrui Medicine Co Ltd
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievement
        15.8.4    Merger and Acquisitions
        15.8.5    Certifications
    15.9    Nodus Oncology 
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievement
        15.9.4    Merger and Acquisitions
        15.9.5    Certifications
    15.10    Abbive, Inc.
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievement
        15.10.4    Merger and Acquisitions
        15.10.5    Certifications
    15.11    Theravance Biopharma, Inc.
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievement
        15.11.4    Merger and Acquisitions
        15.11.5    Certifications
    15.12    Sanofi S.A.
        15.12.1    Company Overview
        15.12.2    Product Portfolio
        15.12.3    Demographic Reach and Achievement
        15.12.4    Merger and Acquisitions
        15.12.5    Certifications
    15.13    Roxane Laboratories Pvt Ltd
        15.13.1    Company Overview
        15.13.2    Product Portfolio
        15.13.3    Demographic Reach and Achievement
        15.13.4    Merger and Acquisitions
        15.13.5    Certifications
    15.14    LGM Pharma Llc
        15.14.1    Company Overview
        15.14.2    Product Portfolio
        15.14.3    Demographic Reach and Achievement
        15.14.4    Merger and Acquisitions
        15.14.5    Certifications
16    Recommendations and Discussion 
17    Pricing Models and Strategies (Additional Insight)

    17.1    Cost Model 
        17.1.1    Manufacturing Cost Analysis 
        17.1.2    Procurement Cost Analysis 
    17.2    Pricing Strategies 
        17.2.1    Competitor Pricing Analysis 
        17.2.2    Key Assessment of Product Attributes 
        17.2.3    Pricing Benchmark 
18    Global Cyclophosphamide Drug Distribution Model (Additional Insight)
    18.1    Overview
    18.2    Potential Distributors
    18.3    Key Parameters for Distribution Partner Assessment

 

*Additional insights provided are customizable as per client requirements

Key Questions Answered in the Report

The market value was about USD 666 million in 2022, driven by the rising cases of cancer.

The market is likely to grow at a CAGR of 2.2% during the forecast period of 2023-2031 to attain a value of USD 806 million by 2031.

Cancers of the ovaries, breast, blood and lymphatic systems, and nerves are all treated with Cyclophosphamide drug (mainly in children). Retinoblastoma, a bone marrow malignancy that primarily affects youngsters, multiple myeloma, and mycosis fungoides, are all treated with Cyclophosphamide drug (tumours on the skin).

The major regions in the global market are North America, Latin America, Asia Pacific, Europe, and Middle East and Africa.

The drug causes various side effects including nausea, vomiting, and appetite loss.

It does not work immediately and usually takes about 6 weeks to start working.

The average percentage of objective responses is 43%. This includes a 38% response rate for individuals who have already received treatment and a 29% response rate for patients who had previously failed to respond to the drug.

In some ANCA-associated vasculitis (AAV) patients, mycophenolate mofetil (MMF) may be a safe and effective substitute for the drug.

The key players in this market include Baxter Laboratories Ltd., Novartis AG, Himka Pharmaceuticals Plc., Amneal Pharmaceuticals LLC, NorthStar Rx LLC, Aurobindo Pharma Ltd., CSC Pharmaceutical International, Jiangsu Hengrui Medicine Co Ltd, Nodus Oncology, Abbive, Inc., Theravance Biopharm, Inc., Sanofi S.A., Roxane Laboratories Pvt Ltd, and LGM Pharma Llc, among others.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER